CancerDrs Find care

Endometrial Cancer clinical trials in Hawaii

6 actively recruiting endometrial cancer trials at 3 sites across Hawaii.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting NIH

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta \[TM\]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo \[TM\]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrin…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05256225
Sites in Hawaii:
  • Queen's Medical Center — Honolulu, Hawaii
  • Kapiolani Medical Center for Women and Children — Honolulu, Hawaii
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

This is a Phase III, 2-arm, randomized, open label, multicenter, global study assessing the efficacy and safety of puxitatug samrotecan compared to physician's choice of chemotherapy (doxorubicin or paclitaxel) in participants with B7-H4 s…

Sponsor: AstraZeneca
NCT ID: NCT07044336
Sites in Hawaii:
  • Research Site — Honolulu, Hawaii
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progress…

Sponsor: AstraZeneca
NCT ID: NCT06989112
Sites in Hawaii:
  • Research Site — Honolulu, Hawaii
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Hawaii:
  • Hawaii Cancer Care Inc - Waterfront Plaza — Honolulu, Hawaii
  • Queen's Cancer Cenrer - POB I — Honolulu, Hawaii
  • Queen's Medical Center — Honolulu, Hawaii
  • Straub Clinic and Hospital — Honolulu, Hawaii
  • University of Hawaii Cancer Center — Honolulu, Hawaii
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite tre…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554328
Sites in Hawaii:
  • Queen's Cancer Cenrer - POB I — Honolulu, Hawaii
  • Queen's Medical Center — Honolulu, Hawaii
  • University of Hawaii Cancer Center — Honolulu, Hawaii
  • Queen's Cancer Center - Kuakini — Honolulu, Hawaii
  • Kapiolani Medical Center for Women and Children — Honolulu, Hawaii
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20